Previous 10 | Next 10 |
United Therapeutics ( UTHR ) Q4 results : Revenues: $381.4M (-17.9%). More news on: United Therapeutics Corporation, Healthcare stocks news, Earnings news and commentary, Read more ...
United Therapeutics (NASDAQ: UTHR ): Q4 Non-GAAP EPS of $3.34 beats by $0.88 ; GAAP EPS of $1.48 misses by $0.98 . More news on: United Therapeutics Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Feb. 27, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the fourth quarter and year ended December 31, 2018 . "2018 was a truly transformative year for United Thera...
United Therapeutics (NASDAQ: UTHR ) is scheduled to announce Q4 earnings results on Wednesday, February 27th, before market open. More news on: United Therapeutics Corporation, Earnings news and commentary, , Healthcare stocks news, Read more ...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Feb. 20, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and annual 2018 financial results before the market opens on Wednesday, February 27, 2019 . United...
The concept of corporate earnings seems pretty straightforward. Sales are reduced by the costs of goods sold to determine a company’s gross margin and to see how profitable its product line is. From that number all other general and administrative expenses are deducted to determine the ...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Jan. 31, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that key data from the FREEDOM-EV study of Orenitram® (treprostinil) extended-release tablets were shared during an oral presentation a...
NEW YORK, Jan. 28, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Realty Income Corporation (NYSE:O), United Therapeutics Corporation (N...
Arena Pharmaceuticals (ARNA) investors have something to celebrate on Jan. 24. The $1.2 billion deal with United Therapeutics (UTHR) has cleared the HSR regulatory review and is now closed. With the closing, Arena received its non-refundable, up-front cash payment of $800 million. There are ...
United Therapeutics (NASDAQ: UTHR ) has closed its license agreement with Arena Pharmaceuticals (NASDAQ: ARNA ). More news on: United Therapeutics Corporation, Arena Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
2024-07-11 06:30:06 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for UTHR on July 11, 2024 04:53AM ET. The previous analyst recommendation was Overweight. UTHR was trading at $329.25 at issue of the analyst recommendation. The overall analyst consensus : ...
Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half of 2025 United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announ...